IBA's Brazil Gambit: A €45M Bet on Latin America's Cancer Care Future

LOUVAIN-LA-NEUVE, Belgium & RIO DE JANEIRO, Brazil – June 25, 2026 – In a move that sends ripples through both the healthcare and technology sectors, Belgian particle accelerator giant IBA has secured a landmark contract to install Brazil's first-ever proton therapy center. The deal, signed with the philanthropic healthcare institution Fundação Severino Sombra (FUSVE), brings IBA's state-of-the-art Proteus®ONE system to Rio de Janeiro, marking a pivotal moment for cancer treatment in Latin America's largest economy.

While the press release highlights a 2030 target for treating the first patients, the implications of this multi-million-euro venture extend far beyond a single hospital wing. This isn't merely a sale; it's a strategic deployment of capital and technology into an emerging market, a calculated move by IBA to solidify its global leadership, and a profound test of Brazil's capacity to integrate and sustain next-generation medical infrastructure.

A Quantum Leap for Brazilian Patients

The clinical need in Brazil is both stark and compelling. Cancer is the leading cause of death by disease for children and adolescents in the country. While incidence rates are comparable to those in developed nations, mortality rates are alarmingly high—nearly double those in the United States. This tragic gap is often attributed to delays in diagnosis and, crucially, a lack of access to specialized treatment centers.

The new Rio de Janeiro center, with its primary focus on pediatric cancer care, aims to directly address this disparity. It will be built around proton therapy, a technology widely considered the pinnacle of radiation treatment. Unlike conventional X-rays that damage healthy tissue along their path, proton beams can be precisely controlled to deposit their cancer-killing energy directly within a tumor and then stop, an effect known as the “Bragg peak.”

For children, whose developing bodies are exceptionally vulnerable to the long-term effects of radiation, this precision is revolutionary. It drastically reduces the risk of collateral damage to vital organs like the brain, heart, and lungs, minimizing the chances of growth defects, cognitive impairment, and secondary, treatment-induced cancers later in life. By one estimate, proton therapy can cut the risk of secondary cancers by half. This technology doesn't just improve survival rates; it fundamentally enhances the future quality of life for young survivors.

Gustavo Oliveira do Amaral, President of FUSVE, captured the project's ambition, stating, “By bringing the first Proteus®️ONE to Brazil, we are taking a historic step in transforming cancer care in our country... Together, we will create a national and regional reference center that will inspire and guide the future of proton therapy in Latin America.” His choice of the word “partner” over “supplier” for IBA is telling, signaling a long-term commitment to building an ecosystem, not just an installation.

The Strategy Behind the Science

From a corporate governance perspective, this deal is a masterclass in strategic market expansion for IBA. With a typical end-user price ranging from €35 to €45 million for a Proteus®ONE system including maintenance, this is a significant capital commitment for FUSVE and a major revenue event for IBA. More importantly, it cements IBA's foothold in a key emerging market.

The company has long claimed the title of world leader in proton therapy, and the numbers often back it up. After capturing a staggering 71% market share in 2022, the company continues to hold a dominant position against formidable competitors like Varian (a Siemens Healthineers company) and Hitachi. This Brazilian contract, the second IBA-equipped center in Latin America, is a clear signal of its intent to replicate that dominance in new territories.

This aggressive expansion is fueled by robust financial performance. IBA recently reported record-high revenues and a return to profitability, supported by a massive €1.5 billion project backlog that provides clear visibility for future growth. The global proton therapy market itself is on an upward trajectory, projected to more than double to $3.72 billion by 2034.

“It is an honor for us to partner with the Severino Sombra Foundation and to contribute to making proton therapy available to patients in Brazil,” commented Olivier Legrain, CEO of IBA. This carefully worded statement underscores the company’s B-Corp certified image, blending its mission-driven rhetoric of accessibility with the hard-nosed business of securing high-value, long-term contracts in untapped markets.

The Proteus®ONE: Engine of Expansion

The choice of the Proteus®ONE system is itself a strategic decision. As a market-leading compact, single-room solution, it is engineered to lower the barriers to entry for institutions venturing into proton therapy. Its smaller footprint and streamlined installation process make it a more financially and logistically viable option compared to older, multi-room behemoths.

But “compact” does not mean compromised. The system is packed with advanced features like Pencil Beam Scanning (PBS), which “paints” the tumor with protons layer by layer with sub-millimeter accuracy. Integrated imaging systems allow for precise patient positioning before each session, ensuring the treatment is as effective and safe as planned. This combination of a lower entry barrier and cutting-edge capability makes the Proteus®ONE an ideal vehicle for market penetration and a powerful tool in IBA’s competitive arsenal.

Furthermore, the system is designed to be scalable and adaptable, with a roadmap for future upgrades. This assuages fears of technological obsolescence—a major concern with any nine-figure capital investment—and positions the Rio center to remain at the forefront of medical innovation for years to come.

The Long Road to Rio 2030

The 2030 go-live date is a sober reminder of the immense complexity involved. Announcing the deal is one thing; executing it is another entirely. FUSVE, IBA, and their scientific partner, the National Cancer Institute (INCA), face a gauntlet of operational and logistical challenges.

First are the regulatory hurdles. Brazil's health regulatory agency, ANVISA, has a complex and evolving framework for high-tech medical devices. Navigating this process will require deep local expertise and patience. Second is the critical challenge of human capital. A proton therapy center requires a small army of highly specialized professionals—medical physicists, dosimetrists, radiation oncologists, and technicians—who are in short supply globally. Building this team from the ground up will be a monumental task of recruitment and training.

Finally, there is the question of long-term financial and operational sustainability. The initial purchase is just the beginning. The multi-year maintenance contract, while securing a recurring revenue stream for IBA, represents a significant ongoing operational expense for FUSVE. Ensuring the center can operate at capacity and serve a broad patient base, including those in the public health system, will be the ultimate test of this ambitious project's success.